Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial
Early terminated late stage (8 days from onset, 59% on oxygen) RCT not showing statistically significant differences. NCT04322396 (history)
risk of death, 92.0% lower, RR 0.08, p = 0.32, treatment 1 of 61 (1.6%), control 2 of 56 (3.6%), adjusted per study.
risk of ICU admission, 22.4% higher, RR 1.22, p = 1.00, treatment 4 of 61 (6.6%), control 3 of 56 (5.4%).
relative days alive and discharged from hospital within 14 days (inverse), 8.4% worse, RR 1.08, p = 0.36, treatment 61, control 56, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sivapalan et al., 3 Jun 2021, Double Blind Randomized Controlled Trial, Denmark, peer-reviewed, 32 authors, average treatment delay 8.0 days, trial NCT04322396 (history)
Abstract: Early View
Azithromycin and hydroxychloroquine in
hospitalised patients with confirmed COVID-19–a
randomised double-blinded placebo-controlled
Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin
Eklöf, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Håkansson, Casper
Tidemandsen, Oliver Tupper, Howraman Meteran, Christina Bergsøe, Eva Brøndum, Uffe Bodtger,
Daniel Bech Rasmussen, Sidse Graff Jensen, Lars Pedersen, Alexander Jordan, Helene Priemé, Christian
Søborg, Ida E. Steffensen, Dorthe Høgsberg, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Peter
Lange, Asger Sverrild, Muhzda Ghanizada, Filip Krag Knop, Tor Biering-Sørensen, Jens D. Lundgren,
Jens-Ulrik Stæhr Jensen,
Please cite this article as: Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, et al. Azithromycin
and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised
double-blinded placebo-controlled trial. Eur Respir J 2021; in press
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is
published here in its accepted form prior to copyediting and typesetting by our production team. After
these production processes are complete and the authors have approved the resulting proofs, the article
will move to the latest issue of the ERJ online.
Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution
Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contactt firstname.lastname@example.org
Azithromycin and hydroxychloroquine in hospitalised
patients with confirmed COVID-19 - a randomised doubleblinded placebo-controlled trial
ProPAC-COVID study group*
*A complete list of members in the Proactive Protection with Azithromycin and hydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID) Study Group is
provided in Supplementary Appendix 3. The ProPAC-COVID study is an initiative by the
independent research network COP:TRIN (www.coptrin.dk).
The members of the writing group (Pradeesh Sivapalan, MD, PhD; Charlotte Suppli Ulrik, MD,
DMSc; Therese Sophie Lapperre, MD, PhD; Rasmus Dahlin Bojesen, MD, PhD; Josefin Eklöf,
MD, PhD; Andrea Browatzki, MD; Jon Torgny Wilcke, MD, PhD; Vibeke Gottlieb, MD, PhD;
Kjell Erik Julius Håkansson, MD; Casper Tidemandsen, MD; Oliver Tupper, MD, PhD;
Howraman Meteran, MD; Christina Bergsøe, BSc; Eva Brøndum, RN; Uffe Bodtger, MD, PhD;
Daniel Bech Rasmussen, MD, PhD; Sidse Graff Jensen, MD, PhD; Lars Pedersen, MD, PhD;
Alexander Jordan, BSc; Helene Priemé, MD, PhD; Christian Søborg, MD, PhD; Ida E.
Steffensen, MD, PhD; Dorthe Høgsberg, RN; Tobias Wirenfeldt Klausen, MSc, PhD; Martin
Steen Frydland, MD, PhD; Peter Lange, MD, DMSc; Asger Sverrild, MD, PhD; Muhzda
Ghanizada, MD; Filip Krag Knop, MD, PhD; Tor Biering-Sørensen, MD, PhD, MPH; Jens D.
Lundgren, MD, DMSc and Jens-Ulrik Stæhr Jensen, MD, PhD [protocol chair, Copenhagen
COP:TRIN lead]) of the ProPAC-COVID Study Group assume responsibility for the overall
content and integrity of this article. The affiliations of the members of the writing group are
listed in the Appendix.
Corresponding author: Professor Jens-Ulrik Stæhr Jensen, COP:TRIN/Department of Medicine,
Herlev-Gentofte Hospital, University of Copenhagen, Denmark. Gentofte hospitalsvej 1, 2900
Hellerup. Phone: +45 2893 8168;..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.